Ken has over 25 years of combined entrepreneurship, investing, clinical medicine, and research experience. Prior to Candid, he served as President and CEO at RayzeBio, a radiopharmaceutical company, from company launch in July 2020 through the $350M+ IPO in September 2023 and then $4.1B acquisition by BMS in February 2024. He also has served as CEO or chairman of Ariosa Diagnostics, Omniome, Metacrine, and Ablaze Pharmaceuticals, all of which have led to successful outcomes and collectively with RayzeBio provided over $5.5B in realized value to shareholders. He also currently serves as executive chairman of Averto Medical, board director at Perceptive Capital Solutions Corp, and board director at ElevAAte, a non-profit organization for East Asian American leadership in biopharma. Earlier in his career, Ken was a venture capitalist at Venrock and a consultant at McKinsey & Company. Ken received a B.S. in biology from MIT and an M.D. from UCSF. Ken trained in internal medicine at UCSF and gastroenterology and hepatology at the University of Washington, and was a scientific research fellow at the Fred Hutchinson Cancer Center.